Paediatrics

Genetics researcher
#Gene therapy #Genespire #Genetic diseases #Paediatrics

Long-term study to inform gene therapy development

Genespire has commenced patient enrolment in an observational study, InforMMA, in children with methylmalonic acidemia (MMA) caused by mutations in the MMUT gene.  The study is designed to follow patients aged up to 16 years who live with severe MMA, with the aim of better characterising disease… Read More

#News

Achondroplasia on ultrasound
#Ascendis Pharma #Clinical trials #Paediatrics

Ascendis provides update on achondroplasia programmes

Ascendis Pharma has provided updates across its achondroplasia programme, including data from the COACH and ApproaCH trials.  Combination therapy update  The company announced that treatment with the combination of once-weekly TransCon CNP and once-weekly TransCon hGH has continued to demonstrate durable growth in children with… Read More

#News

Blood cells
#FDA #Gene therapy #Paediatrics #Sickle cell disorder (SCD)

FDA expands use of Casgevy to children as young as two

The US Food and Drug Administration (FDA) has expanded the use of Casgevy (exagamglogene autotemcel) for the treatment of people ages two years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT).   The approval makes Casgevy the first… Read More

#News #Regulatory

Sickle cells
#Gene therapy #Paediatrics #Sickle cell disorder (SCD) #Vertex

Vertex presents new data on Casgevy in children

Vertex Pharmaceuticals has announced data demonstrating the clinical benefits of Casgevy (exagamglogene autotemcel) in people ages five years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT).   The results, from pivotal studies in children ages 5–11, show that the efficacy and safety… Read More

#News

Doctor holding x-ray
#Clinical trial design #Clinical trials #Oncology #Osteosarcoma #Paediatrics

Novel regulatory science considerations in osteosarcoma: the imperative for regulatory flexibility to meet critical unmet patient and clinical needs

Introduction Rare diseases, as classified by the FDA and EMA, are conditions that affect fewer than 200,00 people in the US1 or fewer than five in 10,000 people in the EU2. Because of these small populations, rare diseases often face unique – and some respects potentially… Read More

#Exclusive Content

Boy tests his blood sugar levels at home
#GLP-1 #Novo Nordisk #Paediatrics #Phase III trial #Type 2 diabetes

Semaglutide could be first oral GLP-1 RA therapy for children

Positive topline results from Novo Nordisk’s PIONEER TEENS, a Phase IIIa trial evaluating oral semaglutide for type 2 diabetes demonstrated a superior reduction in HbA1c (a measure of blood sugar control) over placebo.  The trial, in children and adolescents aged 10–17 years with type 2 diabetes, also… Read More

#News

Cell and gene therapy
#FDA #Gene therapy #Paediatrics #Rare disease #Rocket Pharmaceuticals

First gene therapy for rare paediatric disease gets US approval

The US Food and Drug Administration (FDA) has granted accelerated approval for Kresladi (marnetegragene autotemcel), an autologous haematopoietic stem cell-based gene therapy.  It is indicated for the treatment of paediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) due to biallelic variants in ITGB2 without an available human… Read More

#News #Regulatory #Trending News

Modern medical science laboratory
#Cancer research #Oncology #Paediatrics

C-Further announces oncology therapeutic programmes 

C-Further has unveiled its first early-stage therapeutic programmes dedicated to paediatric oncology indications.  The international consortium is set to advance CF-012 for the treatment of Ewing sarcoma, in collaboration with investigators at UVA Comprehensive Cancer Center, Dana-Farber Cancer Institute and Mass General Brigham, and has also partnered with MiNK Therapeutics to… Read More

#Cancer Research #News

#Ascendis Pharma #BioIndustry Association #Cancer therapy #CHMP #Clinical trial #Diversity #European Medicines Agency #FDA #Gene therapy #Oncology #Paediatrics #Rare disease #uniQure #University of Queensland #Women in STEM

DDW Highlights: 10 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, figures showed the number of women in biotech leadership has stalled. Elsewhere, could… Read More

#Podcasts

Stamp of approval
#Accelerated assessment #Ascendis Pharma #FDA #Paediatrics #Rare disease

FDA approves first once-weekly achondroplasia therapy

The US Food & Drug Administration (FDA) has granted approval for Yuviwel (navepegritide) under its Accelerated Approval Program.  Navepegritide is the only once-weekly treatment indicated to increase linear growth in children one years of age and older with achondroplasia with open epiphyses and the only one to… Read More

#News #Regulatory

Osteosarcoma
#Oncology #Osteosarcoma #Paediatrics

Looking back to see forward: The future of osteosarcoma treatment

An overview of osteosarcoma epidemiology and treatment landscape to guide the future of therapeutic intervention. Osteosarcoma is a rare, aggressive form of bone cancer primarily affecting children and young adults. It is well recognised there continues to exist a critical unmet need in paediatric oncology due… Read More

#Exclusive Content

Map of Canada
#Duchenne muscular dystrophy #Health Canada #Paediatrics #Santhera Pharmaceuticals

First Duchenne muscular dystrophy treatment approved in Canada

The first treatment for Duchenne muscular dystrophy (DMD) has been approved in Canada. Santhera Pharmaceuticals announced that Health Canada approved the company’s Agamree (vamorolone) therapy for DMD in patients four years and older. DMD is a rare inherited X-chromosome-linked disease primarily affecting males. It is characterised by… Read More

#News #Regulatory

Human heart
#Cardiovascular disease #Cell therapy #Longeveron #Paediatrics #Phase II trial #Regenerative Medicine

Regenerative cell therapy for rare heart disease enters PhII trials

Longeveron has completed enrolment for its Phase IIb clinical trial (ELPIS II) evaluating cellular therapy laromestrocel as a potential adjunct treatment for Hypoplastic Left Heart Syndrome (HLHS).  Laromestrocel is a scalable, allogeneic cellular therapy being evaluated in multiple indications.  Top-line trial results are anticipated in… Read More

#News

Children excerising
#Ageing #Multiple sclerosis #Paediatrics #University of California San Diego

Evidence suggests accelerated ageing in children with MS

Researchers from University of California San Diego School of Medicine have discovered that children living with multiple sclerosis (MS) show signs of accelerated biological ageing, even in their teenage years.   The research published in Neurology, the medical journal of the American Academy of Neurology, is… Read More

#News